Download
journal.pone.0266218.pdf 835,12KB
WeightNameValue
1000 Titel
  • Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
1000 Autor/in
  1. Luks, Valerie L. |
  2. Mandl, Hanna |
  3. DiRito, Jenna |
  4. Barone, Christina |
  5. Freedman-Weiss, Mollie R. |
  6. Ricciardi, Adele S. |
  7. Tietjen, Gregory G. |
  8. Egan, Marie E. |
  9. Saltzman, W. Mark |
  10. Stitelman, David |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-04-06
1000 Erschienen in
1000 Quellenangabe
  • 17(4):e0266218
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0266218 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986008/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Advances in Molecular Therapy have made gene editing through systemic or topical administration of reagents a feasible strategy to treat genetic diseases in a rational manner. Encapsulation of therapeutic agents in nanoparticles can improve intracellular delivery of therapeutic agents, provided that the nanoparticles are efficiently taken up within the target cells. In prior work we had established proof-of-principle that nanoparticles carrying gene editing reagents can mediate site-specific gene editing in fetal and adult animals in vivo that results in functional disease improvement in rodent models of β-thalassemia and cystic fibrosis. Modification of the surface of nanoparticles to include targeting molecules (e.g. antibodies) holds the promise of improving cellular uptake and specific cellular binding. METHODS AND FINDINGS: To improve particle uptake for diseases of the airway, like cystic fibrosis, our group tested the impact of nanoparticle surface modification with cell surface marker antibodies on uptake in human bronchial epithelial cells in vitro. Binding kinetics of antibodies (Podoplanin, Muc 1, Surfactant Protein C, and Intracellular Adhesion Molecule-1 (ICAM)) were determined to select appropriate antibodies for cellular targeting. The best target-specific antibody among those screened was ICAM antibody. Surface conjugation of nanoparticles with antibodies against ICAM improved cellular uptake in bronchial epithelial cells up to 24-fold. CONCLUSIONS: This is a first demonstration of improved nanoparticle uptake in epithelial cells using conjugation of target specific antibodies. Improved binding, uptake or specificity of particles delivered systemically or to the luminal surface of the airway would potentially improve efficacy, reduce the necessary dose and thus safety of administered therapeutic agents. Incremental improvement in the efficacy and safety of particle-based therapeutic strategies may allow genetic diseases such as cystic fibrosis to be cured on a fundamental genetic level before birth or shortly after birth.
1000 Sacherschließung
lokal Gene delivery
lokal Antibody isotypes
lokal Nanoparticles
lokal Antibody therapy
lokal Epithelial cells
lokal Flow cytometry
lokal Cell staining
lokal Cystic fibrosis
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/THVrcywgVmFsZXJpZSBMLg==|https://frl.publisso.de/adhoc/uri/TWFuZGwsIEhhbm5h|https://orcid.org/0000-0002-8513-5937|https://frl.publisso.de/adhoc/uri/QmFyb25lLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/uri/RnJlZWRtYW4tV2Vpc3MsIE1vbGxpZSBSLg==|https://frl.publisso.de/adhoc/uri/UmljY2lhcmRpLCBBZGVsZSBTLg==|https://frl.publisso.de/adhoc/uri/VGlldGplbiwgR3JlZ29yeSBHLg==|https://frl.publisso.de/adhoc/uri/RWdhbiwgTWFyaWUgRS4=|https://frl.publisso.de/adhoc/uri/U2FsdHptYW4sIFcuIE1hcms=|https://orcid.org/0000-0001-8067-5830
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. Cystic Fibrosis Foundation |
  2. National Institutes of Health |
1000 Fördernummer
  1. DHS STITEL17GO
  2. WMS UG3- HL147352
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Cystic Fibrosis Foundation |
    1000 Förderprogramm -
    1000 Fördernummer DHS STITEL17GO
  2. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer WMS UG3- HL147352
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6452917.rdf
1000 Erstellt am 2023-06-26T06:50:07.623+0200
1000 Erstellt von 337
1000 beschreibt frl:6452917
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-01T11:47:52.077+0200
1000 Objekt bearb. Tue Aug 01 11:47:36 CEST 2023
1000 Vgl. frl:6452917
1000 Oai Id
  1. oai:frl.publisso.de:frl:6452917 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source